

C1  
B1  
C1 comprising an alpha (2) macroglobulin polypeptide noncovalently associated with an antigenic molecule which displays the antigenicity of (i) an antigen of an infectious agent or (ii) an antigen overexpressed in a cell of a proliferative disorder relative to its expression in a cell of said cell type that is not of said proliferative disorder.

---

B2 3 (amended). The pharmaceutical composition of Claim 1 wherein the proliferative disorder is cancer and wherein the antigenic molecule displays the antigenicity of an antigen overexpressed in a cancer cell relative to its expression in a noncancerous cell of said cell type.

---

C1  
B3 7. (amended) A purified molecular complex comprising an alpha (2) macroglobulin polypeptide noncovalently associated with an antigenic molecule of an infectious agent or an antigen overexpressed in a cell of a proliferative disorder cell relative to its expression in a cell of said cell type that is not of said proliferative disorder.

---

Please add new claims 37-42 as follows:

37 (new). The purified molecular complex of Claim 7 wherein the antigenic molecule displays the antigenicity of an antigen of an infectious agent.

38 (new). The purified molecular complex of Claim 7 wherein the proliferative cell disorder is cancer and wherein the antigenic molecule displays the antigenicity of an antigen overexpressed in a cancer cell relative to its expression in a noncancerous cell of said cell type.

---

B4 39 (new). The purified molecular complex of Claim 7 wherein the antigenic molecule is a tumor specific antigen or a tumor-associated antigen.

SUB C1 40 (new). The purified molecular complex of Claim 7 wherein the alpha (2) macroglobulin polypeptide and/or the antigenic molecule are chemically synthesized or recombinantly produced.

41 (new). The pharmaceutical composition of Claim 1 comprising an amount of a purified molecular complex effective for treatment or prevention of an infectious disease, wherein the infectious disease is caused by a pathogen selected from the group consisting of hepatitis type B virus, adeno-associated virus, cytomegalovirus, papilloma virus, polyoma viruses, SV40, herpes simplex type I (HSV-I), herpes simplex type II (HSV-II), Epstein-Barr virus, variola (smallpox), vaccinia virus, human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), human T-cell lymphotropic virus type I (HTLV-I), human T-cell lymphotropic virus type II (HTLV-II), influenza virus, measles virus, rabies virus, Sendai virus, poliomyelitis virus, coxsackieviruses, rhinoviruses, reoviruses, rubella virus (German measles) Semliki forest virus, arboviruses, hepatitis type A virus, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter (Vibrio) fetus*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Salmonella typhi*, *Treponema pallidum*, *Treponema pertenue*, *Treponema carateneum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma spp.*, *Rickettsia prowazekii*, *Rickettsia tsutsugumushi*, *Chlamydia spp.*, *Helicobacter pylori*, *Entamoeba histolytica*, *Trichomonas tenax*, *Trichomonas hominis*, *Trichomonas vaginalis*, *Trypanosoma gambiense*, *Trypanosoma rhodesiense*, *Trypanosoma cruzi*, *Leishmania donovani*, *Leishmania tropica*, *Leishmania braziliensis*, *Pneumocystis pneumonia*, *Plasmodium vivax*, *Plasmodium falciparum*, and *Plasmodium malaria*.

42 (new). The pharmaceutical composition of Claim 1 comprising an amount of a purified molecular complex effective for treatment or prevention of a proliferative cell disorder selected from the group consisting of fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's